LAVA Therapeutics N.V.
LVTX
$1.61
-$0.01-0.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.38M | -28.04M | -25.17M | -27.60M | -24.14M |
| Total Depreciation and Amortization | 107.00K | 219.00K | 256.00K | 162.00K | 268.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.63M | -3.15M | 1.75M | 4.79M | 2.46M |
| Change in Net Operating Assets | -3.52M | 1.08M | 4.07M | -6.82M | -6.53M |
| Cash from Operations | -35.43M | -29.89M | -19.09M | -29.46M | -27.94M |
| Capital Expenditure | -23.00K | 0.00 | -23.00K | -24.00K | -7.00K |
| Sale of Property, Plant, and Equipment | 279.00K | -1.00K | 88.00K | 94.00K | 92.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.82M | 26.94M | 12.41M | -7.25M | -24.57M |
| Cash from Investing | 24.08M | 26.94M | 12.48M | -7.18M | -24.48M |
| Total Debt Issued | -259.00K | -259.00K | -259.00K | -259.00K | -235.00K |
| Total Debt Repaid | -317.00K | -317.00K | -317.00K | 625.00K | 489.00K |
| Issuance of Common Stock | 2.00K | 18.00K | 26.00K | 26.00K | 24.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -574.00K | -558.00K | -550.00K | 392.00K | 278.00K |
| Foreign Exchange rate Adjustments | 3.22M | 0.00 | -2.05M | 556.00K | -378.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.71M | -3.51M | -9.22M | -35.70M | -52.52M |